Noninvasive Imaging of Early Venous Thrombosis by 19F Magnetic Resonance Imaging With Targeted Perfluorocarbon Nanoemulsions

Background— Noninvasive detection of deep venous thrombi and subsequent pulmonary thromboembolism is a serious medical challenge, since both incidences are difficult to identify by conventional ultrasound techniques. Methods and Results— Here, we report a novel technique for the sensitive and specific identification of developing thrombi using background-free 19F magnetic resonance imaging, together with &agr;2-antiplasmin peptide (&agr;2AP)–targeted perfluorocarbon nanoemulsions (PFCs) as contrast agent, which is cross-linked to fibrin by active factor XIII. Ligand functionality was ensured by mild coupling conditions using the sterol-based postinsertion technique. Developing thrombi with a diameter <0.8 mm could be visualized unequivocally in the murine inferior vena cava as hot spots in vivo by simultaneous acquisition of anatomic matching 1H and 19F magnetic resonance images at 9.4 T with both excellent signal-to-noise and contrast-to-noise ratios (71±22 and 17±5, respectively). Furthermore, &agr;2AP-PFCs could be successfully applied for the diagnosis of experimentally induced pulmonary thromboembolism. In line with the reported half-life of factor XIIIa, application of &agr;2AP-PFCs >60 minutes after thrombus induction no longer resulted in detectable 19F magnetic resonance imaging signals. Corresponding results were obtained in ex vivo generated human clots. Thus, &agr;2AP-PFCs can visualize freshly developed thrombi that might still be susceptible to pharmacological intervention. Conclusions— Our results demonstrate that 1H/19F magnetic resonance imaging, together with &agr;2AP-PFCs, is a sensitive, noninvasive technique for the diagnosis of acute deep venous thrombi and pulmonary thromboemboli. Furthermore, ligand coupling by the sterol-based postinsertion technique represents a unique platform for the specific targeting of PFCs for in vivo 19F magnetic resonance imaging.

[1]  Peter M. Jakob,et al.  In Vivo Imaging of Stepwise Vessel Occlusion in Cerebral Photothrombosis of Mice by 19F MRI , 2011, PloS one.

[2]  P. Jakob,et al.  In vivo imaging of inflammation in the peripheral nervous system by 19F MRI , 2011, Experimental Neurology.

[3]  P. Jakob,et al.  Visualization of inflammation using (19) F-magnetic resonance imaging and perfluorocarbons. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[4]  A. Houng,et al.  The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. , 1999, Circulation.

[5]  W. Backes,et al.  Clinical Perspectives of Hybrid Proton-Fluorine Magnetic Resonance Imaging and Spectroscopy , 2013, Investigative radiology.

[6]  F. Sampson,et al.  The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis , 2006, European Radiology.

[7]  Sebastian Temme,et al.  19F magnetic resonance imaging of endogenous macrophages in inflammation. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[8]  René M. Botnar,et al.  MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients , 2008, European Radiology.

[9]  G. Nenci,et al.  Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. , 1998, The Journal of clinical investigation.

[10]  P. Heusch,et al.  Visualization of immune cell infiltration in experimental viral myocarditis by 19F MRI in vivo , 2014, Magnetic Resonance Materials in Physics, Biology and Medicine.

[11]  Zahi A Fayad,et al.  Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent , 2005, Circulation.

[12]  Elmar Spuentrup,et al.  Thrombus Imaging With Fibrin-Specific Gadolinium-Based MR Contrast Agent EP-2104R: Results of a Phase II Clinical Study of Feasibility , 2009, Investigative radiology.

[13]  K. Ohlsen,et al.  Visualization of Abscess Formation in a Murine Thigh Infection Model of Staphylococcus aureus by 19F-Magnetic Resonance Imaging (MRI) , 2011, PloS one.

[14]  M. Olschewski,et al.  Novel Single-Chain Antibody-Targeted Microbubbles for Molecular Ultrasound Imaging of Thrombosis: Validation of a Unique Noninvasive Method for Rapid and Sensitive Detection of Thrombi and Monitoring of Success or Failure of Thrombolysis in Mice , 2012, Circulation.

[15]  René M. Botnar,et al.  Molecular Coronary MR Imaging of Human Thrombi using EP-2104R, a Fibrin-Targeted Contrast Agent: Experimental Study in a Swine Model , 2007, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[16]  B. A. French,et al.  Early Assessment of Pulmonary Inflammation by 19F MRI In Vivo , 2010, Circulation. Cardiovascular imaging.

[17]  R. Weissleder,et al.  Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway. , 2012, JACC. Cardiovascular imaging.

[18]  U. Flögel,et al.  Technical Advance: Monitoring the trafficking of neutrophil granulocytes and monocytes during the course of tissue inflammation by noninvasive 19F MRI , 2014, Journal of leukocyte biology.

[19]  Rolf Schubert,et al.  Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half‐lives and sensitivity , 2014, NMR in biomedicine.

[20]  Rolf Schubert,et al.  In Vivo Monitoring of Inflammation After Cardiac and Cerebral Ischemia by Fluorine Magnetic Resonance Imaging , 2008, Circulation.

[21]  R. Weissleder,et al.  Molecular Imaging of Factor XIIIa Activity in Thrombosis Using a Novel, Near-Infrared Fluorescent Contrast Agent That Covalently Links to Thrombi , 2004, Circulation.

[22]  Mangala Srinivas,et al.  Fluorine‐19 MRI for visualization and quantification of cell migration in a diabetes model , 2007, Magnetic resonance in medicine.

[23]  P. Duffy,et al.  Colour Doppler ultrasound in deep venous thrombosis: a comparison with venography. , 1990, Clinical radiology.

[24]  F. Sampson,et al.  Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta-analysis. , 2008, Clinical radiology.

[25]  René M. Botnar,et al.  Fibrin-Targeted Magnetic Resonance Imaging Allows In Vivo Quantification of Thrombus Fibrin Content and Identifies Thrombi Amenable for Thrombolysis , 2014, Arteriosclerosis, Thrombosis and Vascular Biology.

[26]  Eric T Ahrens,et al.  In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.

[27]  J. V. van Engelshoven,et al.  Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. , 2009, JACC. Cardiovascular imaging.

[28]  T. Hitchens,et al.  A novel probe for the non-invasive detection of tumor-associated inflammation , 2013, Oncoimmunology.

[29]  R. Murthy,et al.  Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[30]  A. Houng,et al.  Catalytic Life of Activated Factor XIII in Thrombi: Implications for Fibrinolytic Resistance and Thrombus Aging , 2000, Circulation.

[31]  D. Laidlaw,et al.  In vivo cytometry of antigen‐specific t cells using 19F MRI , 2009, Magnetic resonance in medicine.

[32]  C. Müller,et al.  Selective Activation of Adenosine A2A Receptors on Immune Cells by a CD73-Dependent Prodrug Suppresses Joint Inflammation in Experimental Rheumatoid Arthritis , 2012, Science Translational Medicine.

[33]  J. Bulte,et al.  Tracking immune cells in vivo using magnetic resonance imaging , 2013, Nature Reviews Immunology.

[34]  V. Fuster,et al.  Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. , 2005, Atherosclerosis.

[35]  René M. Botnar,et al.  Molecular Magnetic Resonance Imaging of Atrial Clots in a Swine Model , 2005, Circulation.

[36]  S. Caruthers,et al.  Characterization of early neovascular response to acute lung ischemia using simultaneous 19F/1H MR molecular imaging , 2013, Angiogenesis.

[37]  René M. Botnar,et al.  Molecular Magnetic Resonance Imaging of Coronary Thrombosis and Pulmonary Emboli With a Novel Fibrin-Targeted Contrast Agent , 2005, Circulation.

[38]  Paul D Stein,et al.  Obesity as a risk factor in venous thromboembolism. , 2005, The American journal of medicine.

[39]  René M. Botnar,et al.  Molecular MR Imaging of Human Thrombi in a Swine Model of Pulmonary Embolism Using a Fibrin-Specific Contrast Agent , 2007, Investigative radiology.

[40]  S. Middeldorp,et al.  Cancer and Venous Thrombosis: Current Comprehensions and Future Perspectives , 2013, Seminars in Thrombosis & Hemostasis.

[41]  Eric T Ahrens,et al.  Accelerated fluorine‐19 MRI cell tracking using compressed sensing , 2013, Magnetic resonance in medicine.

[42]  U. Flögel,et al.  Noninvasive Detection of Graft Rejection by In Vivo 19F MRI in the Early Stage , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[43]  Ralph Weissleder,et al.  Novel Factor XIII Probes for Blood Coagulation Imaging , 2003, Chembiochem : a European journal of chemical biology.

[44]  19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles , 2012, Angiogenesis.

[45]  René M. Botnar,et al.  Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. , 2005, American journal of respiratory and critical care medicine.